CoQ10
Evidence Fact Sheet
Ubiquinone / Ubiquinol
Coenzyme Q10 (ubiquinone/ubiquinol) is a mitochondrial electron-transport cofactor and lipid-phase antioxidant. Human evidence is strongest for chronic heart failure (Q-SYMBIO RCT) and modest blood-pressure lowering; statin-myopathy and male-fertility data are mixed, with honest null findings on inflammation and live-birth rates.
Also known as: Coenzyme Q10 · Ubiquinone-10 · Ubidecarenone · Ubiquinol (reduced form)
Overview
CoQ10 (Coenzyme Q10), in its oxidized ubiquinone or reduced ubiquinol form, is an endogenous lipophilic cofactor that shuttles electrons in the mitochondrial respiratory chain (Complexes I-III), supports ATP biosynthesis, and acts as a lipid-phase antioxidant; it is also studied as a rescue for statin-induced CoQ10 depletion. Typical research doses are 100-300 mg/day ubiquinone or 100-200 mg/day ubiquinol (better absorbed in older adults), with the landmark Q-SYMBIO heart-failure trial using 100 mg three times daily; it is fat-soluble and best taken with food. It is generally well tolerated, with a theoretical warfarin interaction noted due to its vitamin-K-like quinone structure. Regulatory status: FDA-permitted dietary supplement under DSHEA (structure/function claims); EFSA rejected its health claims in 2010 (permitted as a food supplement); ANVISA permits it as a dietary supplement without authorized functional claims; China SAMR lists ubidecarenone in the Health Food raw-material catalogue with authorized immune-enhancement and antioxidant functions at 30-50 mg/day. This page frames all findings as research outcomes in studied populations, not as disease treatment.
Mechanism of Action
Mitochondrial electron transport chain (Complex I-III shuttle) · Lipid-phase antioxidant · ATP biosynthesis cofactor · Statin-induced CoQ10 depletion rescue
Body systems: Cardiovascular · Mitochondrial & Cellular Energy · METABOLISM · Reproductive
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — CoQ10 is not characterized as a treatment for any disease.
Chronic Heart Failure (Adjunct)
RCT supported- HR 0.50MACE · p=0.003
- 15% vs 26%primary endpoint · CoQ10 vs placebo
- 10% vs 18%all-cause mortality · p=0.018
The landmark Q-SYMBIO randomized double-blind trial (n=420, 100 mg three times daily, 2-year follow-up) is the strongest human signal for CoQ10. The composite primary endpoint of major adverse cardiovascular events occurred in 15% of the CoQ10 group versus 26% on placebo, with significantly lower all-cause and cardiovascular mortality. This is a single trial in heart-failure patients on standard therapy, not a treatment claim.
Reported effect: Primary endpoint 15% (CoQ10) vs 26% (placebo); HR 0.50 (95% CI 0.32-0.80; p=0.003); CV mortality 9% vs 16% (p=0.026); all-cause mortality 10% vs 18% (p=0.018); n=420; 2-year follow-up
“The primary long-term endpoint was reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003). ... Cardiovascular mortality: 9% vs. 16%, p = 0.026 ... All-cause mortality: 10% vs. 18%, p = 0.018”
Source: PMID 25282031 · Mortensen 2014 · JACC Heart Fail
Blood Pressure (Cardiometabolic Patients)
Meta-analysis supported- -4.77 mmHgsystolic BP · pooled
- 26 RCTs1,831 participants
- moderateGRADE certainty · SBP
A GRADE-assessed dose-response meta-analysis of 26 RCTs (1,831 participants) found CoQ10 significantly lowered systolic blood pressure by about 4.77 mmHg in patients with cardiometabolic disorders, with a U-shaped dose-response suggesting 100-200 mg/day is optimal. The evidence certainty was rated moderate for systolic but lower for diastolic BP, so the effect is real but modest.
Reported effect: SBP -4.77 mmHg (95% CI -6.57 to -2.97); 26 RCTs, 1,831 participants; GRADE certainty moderate for SBP; optimal dose 100-200 mg/d (U-shaped dose-response)
“CoQ10 supplementation significantly reduced systolic blood pressure (SBP) (-4.77 mmHg, 95% CI: -6.57, -2.97) ... 26 randomized controlled trials with 1,831 participants ... The quality of evidence was rated as moderate, low, and very low for SBP, diastolic blood pressure (DBP), and circulating CoQ10 ... according to ... GRADE”
Source: PMID 36130103 · Zhao 2022 · Adv Nutr
Statin-Associated Muscle Symptoms (No Benefit)
Null / no benefit Meta-analysis supported- WMD -0.42myalgia · CI -1.47 to 0.62
- 7 RCTs321 patients
- RR 0.99statin adherence · ns
Despite the popular rationale that statins deplete CoQ10, a meta-analysis of 7 RCTs (321 patients) found no significant benefit of CoQ10 on statin-associated myalgia, and no improvement in staying on statin therapy. The confidence intervals crossed zero on both outcomes. This is one of CoQ10's well-known honest negatives.
Reported effect: Myalgia weighted mean difference -0.42 (95% CI -1.47 to 0.62), non-significant; statin adherence RR 0.99 (95% CI 0.81 to 1.20); 7 RCTs, 321 patients
“The meta-analysis did not demonstrate any benefit of CoQ10 supplementation in improving myalgia symptoms compared to placebo (weighted mean difference -0.42; 95% Confidence Interval [CI] -1.47 to 0.62). ... CoQ10 did not improve the proportion of patients remaining on the statin treatment (RR 0.99; 95%CI, 0.81 to 1.20).”
Source: PMID 32179207 · Kennedy 2020 · Atherosclerosis
Statin Myopathy (Conflicting Newer Pooled Signal)
Meta-analysis supported- WMD -0.96muscle pain · p<0.05
- 7 RCTs389 participants
Counterbalancing the null Kennedy 2020 result, a more recent 2025 meta-analysis of 7 RCTs (389 participants) reported a statistically significant reduction in statin-associated muscle pain intensity with CoQ10. The two pooled analyses disagree, so the statin-myopathy evidence remains genuinely mixed and trial-dependent rather than settled.
Reported effect: Muscle pain intensity weighted mean difference -0.96 (95% CI -1.88 to -0.03, p<0.05); 7 RCTs, 389 participants
“weighted mean difference (WMD) -0.96 (95% Confidence Interval -1.88; -0.03), p < 0.05 ... Number of studies: 7 ... Number of participants: 389”
Source: PMID 41158831 · Kovacic 2025 · J Nutr Sci
Migraine Prophylaxis
Meta-analysis supported- MD -1.52migraine frequency · p<0.001
- MD -0.19attack duration · p<0.00001
- 6 trials371 participants
A meta-analysis of 6 trials (371 participants) found CoQ10 reduced both migraine frequency (MD -1.52 attacks) and headache duration versus control, with no heterogeneity (I2=0%). Importantly, it did NOT significantly reduce migraine severity, so the benefit appears specific to how often and how long attacks occur, not how intense they are.
Reported effect: Migraine frequency MD -1.52 (95% CI -2.40 to -0.65, p<0.001, I2=0%); duration MD -0.19 (95% CI -0.27 to -0.11, p<0.00001); severity: no significant reduction; 6 trials, 371 participants
“CoQ10 usage reduced the frequency of migraine headache compared with the control group (MD: -1.52; 95% CI: -2.40 to -0.65; random effects; I2 statistic=0%; p<0.001) ... reduced the duration of headache attacks ... (MD: -0.19; 95% CI: -0.27 to -0.11 ... p<0.00001) ... There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation”
Source: PMID 33402403 · Sazali 2021 · BMJ Open
Male Fertility / Sperm Parameters
Null / no benefit Meta-analysis supported- RR 4.50sperm motility · CI 3.92-5.08
- RR 5.33sperm concentration
A meta-analysis of 3 trials (149 CoQ10 vs 147 placebo) found CoQ10 improved sperm motility and concentration. However, no included trial reported live births, and CoQ10 did not increase pregnancy rates, so the clinically meaningful endpoint (a baby) shows no proven benefit. This is a key honest negative for the fertility use case.
Reported effect: Sperm motility RR 4.50 (95% CI 3.92-5.08, I2=0%); sperm concentration RR 5.33 (95% CI 4.18-6.47, I2=58%); no live-birth data reported; no increase in pregnancy rates; 3 trials, 149 vs 147
“Sperm motility: RR 4.50, 95 % CI 3.92 to 5.08, I(2) = 0 % ... Sperm concentration: RR 5.33, 95 % CI 4.18 to 6.47, I(2) = 58 % ... None of the included trials provided any data regarding live births. ... supplementing infertile men with CoQ10 does not increase pregnancy rates.”
Source: PMID 23912751 · Lafuente 2013 · J Assist Reprod Genet
Inflammation / C-Reactive Protein (Null)
Null / no benefit Meta-analysis supported- -0.25 mg/LCRP · CI -0.56 to 0.06
- 7 studiesnon-significant
A meta-analysis of 7 trials found CoQ10's effect on plasma C-reactive protein, a marker of systemic inflammation, was not statistically significant: the pooled change of -0.25 mg/L had a confidence interval crossing zero. So despite CoQ10's antioxidant biochemistry, pooled human data do not show a reliable anti-inflammatory CRP effect.
Reported effect: Plasma CRP WMD -0.25 mg/L (95% CI -0.56 to 0.06, I2=42.0%), non-significant (CI crosses zero); 7 studies
“weighted mean difference [WMD] of -0.25mg/l (95% confidence intervals [CI] -0.56 to 0.06, I2=42.0%) ... 7 studies were included”
Source: PMID 28847708 · Mazidi 2018 · Pharmacol Res
Glycemic Control / Antioxidant Capacity (Type 2 Diabetes)
RCT supported- HbA1c ↓p=0.03 · ubiquinol group
- catalase ↑p<0.01
A double-blind RCT of liquid ubiquinol in type 2 diabetes patients found HbA1c significantly decreased in the ubiquinol group (p=0.03) and antioxidant enzyme activities (catalase, glutathione peroxidase) increased significantly. Lipid profiles did not change. This is a single trial, so the glycemic signal is preliminary rather than established.
Reported effect: HbA1c significantly decreased in ubiquinol group (P=0.03); catalase activity increased (P<0.01); glutathione peroxidase increased (P=0.03); lipid profiles unchanged
“glyco Hb (HbA1c) value was significantly decreased in the liquid ubiquinol group (P=0·03) ... Lipid profiles did not change after supplementation ... The catalase (P<0·01) and glutathione peroxidase (P=0·03) activities were increased significantly after supplementation”
Source: PMID 29936921 · Yen 2018 · Br J Nutr
Dosage (research context · not a recommendation)
100-300 mg/day ubiquinone; 100-200 mg/day ubiquinol (better absorbed >50yo); Q-SYMBIO HF 100 mg t.i.d.
Regulatory Status · 4 Markets
- US · FDA
- GRAS · DSHEA dietary supplement; structure/function claims permitted
- EU · EFSA
- No authorized health claim (claims rejected 2010); permitted as food supplement
- CN · China
- China SAMR: ubidecarenone (CoQ10) listed in Health Food Raw Material Catalogue (2021, filing route) with two authorized functions immune-enhancement + antioxidant; 30-50 mg/day; general food cannot make claims.
- BR · ANVISA
- RDC 243/2018 dietary supplement · IN 28/2018 alegação funcional not authorized
Safety
Generally well tolerated; theoretical warfarin interaction (vitamin K-like quinone structure); take with fat for absorption
Related
Goals: heart-health · longevity-stack · athletic-performance · reproductive-health
Lifestyles: senior-60-plus · senior-60-plus · high-stress
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 25282031 · Mortensen 2014 · JACC Heart Fail — Chronic Heart Failure (Adjunct)
- PMID 36130103 · Zhao 2022 · Adv Nutr — Blood Pressure (Cardiometabolic Patients)
- PMID 32179207 · Kennedy 2020 · Atherosclerosis — Statin-Associated Muscle Symptoms (No Benefit)
- PMID 41158831 · Kovacic 2025 · J Nutr Sci — Statin Myopathy (Conflicting Newer Pooled Signal)
- PMID 33402403 · Sazali 2021 · BMJ Open — Migraine Prophylaxis
- PMID 23912751 · Lafuente 2013 · J Assist Reprod Genet — Male Fertility / Sperm Parameters
- PMID 28847708 · Mazidi 2018 · Pharmacol Res — Inflammation / C-Reactive Protein (Null)
- PMID 29936921 · Yen 2018 · Br J Nutr — Glycemic Control / Antioxidant Capacity (Type 2 Diabetes)
Frequently Asked Questions
1. What is the strongest human evidence for CoQ10?
The landmark Q-SYMBIO randomized double-blind trial (Mortensen 2014, JACC Heart Fail) in 420 chronic heart-failure patients on standard therapy. Using 100 mg three times daily over 2 years, the major adverse cardiovascular event endpoint occurred in 15% of the CoQ10 group versus 26% on placebo (HR 0.50, p=0.003), with lower all-cause mortality (10% vs 18%, p=0.018). This is a research finding in a specific patient population studied alongside standard care, not a treatment claim or substitute for medical therapy.
2. Does CoQ10 actually help statin-related muscle pain?
The evidence is genuinely mixed. A 2020 meta-analysis of 7 RCTs (Kennedy, Atherosclerosis) found no significant benefit on myalgia (WMD -0.42, confidence interval crossing zero) and no improvement in staying on statins. A more recent 2025 meta-analysis (Kovacic, J Nutr Sci) of 7 RCTs did report a significant reduction in muscle pain (WMD -0.96, p<0.05). Because well-conducted pooled analyses disagree, the popular idea that CoQ10 reliably fixes statin muscle symptoms is not settled. Statin decisions should be made with a clinician.
3. Can CoQ10 lower blood pressure?
A GRADE-assessed meta-analysis of 26 RCTs in 1,831 cardiometabolic patients (Zhao 2022, Adv Nutr) found a modest, statistically significant systolic reduction of about 4.77 mmHg, with a U-shaped dose-response pointing to roughly 100-200 mg/day. The certainty of evidence was rated moderate for systolic and lower for diastolic pressure, so the effect is real but small and best viewed as one input alongside established blood-pressure management.
4. Does CoQ10 improve male fertility?
Partially, and with an important caveat. A meta-analysis (Lafuente 2013, J Assist Reprod Genet) found CoQ10 improved sperm motility and concentration. However, no included trial measured live births, and CoQ10 did not increase pregnancy rates. So while sperm-quality markers improve, the outcome that matters most clinically (an actual pregnancy or baby) has not been shown to benefit. This is one of CoQ10's well-known honest negatives.
5. Is CoQ10 anti-inflammatory or good for migraines?
Two different stories. For inflammation, a meta-analysis (Mazidi 2018, Pharmacol Res) found no significant effect on C-reactive protein (-0.25 mg/L, confidence interval crossing zero) — a null result despite CoQ10's antioxidant chemistry. For migraine, a meta-analysis of 6 trials (Sazali 2021, BMJ Open) found CoQ10 reduced attack frequency (MD -1.52) and duration, but NOT severity. So migraine benefits appear specific to how often and how long attacks last, not how intense they feel.
6. Ubiquinone or ubiquinol, and how should it be taken?
CoQ10 comes as oxidized ubiquinone and reduced ubiquinol; ubiquinol tends to be better absorbed, especially in adults over 50. Research doses are typically 100-300 mg/day ubiquinone or 100-200 mg/day ubiquinol, and the Q-SYMBIO heart-failure trial used 100 mg three times daily. Because CoQ10 is fat-soluble, it is best taken with a meal containing fat. It is generally well tolerated, with a theoretical interaction with warfarin (its quinone structure resembles vitamin K), so anyone on anticoagulants should consult a clinician first. Regulatory note: it is a permitted dietary supplement in the US (DSHEA, structure/function claims only); EFSA rejected its health claims in 2010; and China authorizes immune-enhancement and antioxidant functions at 30-50 mg/day.
Last evidence review: 2026-05-29